All Categories
The Truth about Teams
When it comes to team performance and adherence to “best practices,” what works on paper or in a teambuilding workshop and what actually occurs are often two very different things. Not for lack of trying (in most cases!), the practical constraints of time, resources, and human nature often get in the way. Fortunately, there are approaches to… Read the full article… |
Running the Biopharma Marathon
When I moved to Boston over thirty years ago, I had never even heard of the Boston Marathon. I grew up in the Midwest and moved to the West Coast for a district sales manager role. Boston, let alone the Marathon, just wasn’t part of my world. All that changed when I moved to Newton, to a… Read the full article… |
Rare Diseases: Shaping Biopharma’s Future from the Past
We just completed Rare Disease month. With that in mind, Sue has asked me to step in for today’s e-conversation, as this topic is very much a part of my focus and professional experience. A few weeks ago, I conducted a virtual discussion with an esteemed panel of seasoned executives and former Genzyme veterans: Jim Geraghty, Masako… Read the full article… |
“Rare Disease” Is More Than Just a Day
“It is important for all of us to appreciate where we come from and how that history has really shaped us in ways that we might not understand.” Justice Sotomayor You might think it odd for me to begin this month’s e-conversation with a quote from a Supreme Court justice. However, this insight has stuck with me… Read the full article… |
Patient Advocacy – Delivering on Patient Centricity in Drug Development
Historically, biopharma companies developed drugs for patients with an illness — but the illness was the primary focus. In recent years, much has changed. As drug development has become more enlightened, understanding the experience of people living with health conditions — their needs, goals, and the practicalities of daily life — has become integral to the process of… Read the full article… |
Beyond the One-Hit Wonder
Innovation in our industry is extraordinary on so many levels. The science is unparalleled, the collective intellect is exceptional, and the passion for the patient is unwavering. Mobilizing this innovation to discover, develop, and commercialize novel treatments for patients, all while building a company, can be a Herculean task. When we work with emerging companies, we… Read the full article… |
Optimizing Collaboration between Commercial and Medical Affairs
We define commercialization in the biopharma space as a mindset that requires the entire organization to begin with the patient in mind and build an ethos and structure that ensures all aspects of the company are aligned. The purpose, overall, is to make sure the innovative treatment in development reaches the patient population where it will make… Read the full article… |
Survival in Uncertain Times
Like so many seasoned industry professionals, we eagerly seek thought leader perspectives — on the current biopharma industry landscape; the investment strategies purported to be in play; and (of course) the likely true impact of the Inflation Reduction Act in both the near- and mid-term. As leaders in our own domains, it is essential that we hear… Read the full article… |
The Importance of a Commercialization Mindset
We write and speak a great deal about commercialization. It’s central to the work of our clients and, therefore, to ours as well. And so, in a recent panel, we brought together three experts from The NemetzGroup — Colleen Moore, Liz Tufo, and Tracey Sacco — to share their perspectives on the topic. Over the… Read the full article… |
Professionalism Still Matters
Sadly, another summer is coming to a close. If you have school-aged kids at home, you are undoubtedly already taking steps to shake them out of summer mode and get them ready for the new school year with its firm schedule and structure. For many of us working adults, however, the lines are not so… Read the full article… |